Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Assets: 2014-2025

Historic Return on Assets for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to 1.13%.

  • Coherus Oncology's Return on Assets rose 84.00% to 1.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.13%, marking a year-over-year increase of 84.00%. This contributed to the annual value of 0.05% for FY2024, which is 48.00% up from last year.
  • As of Q3 2025, Coherus Oncology's Return on Assets stood at 1.13%, which was down 19.37% from 1.40% recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Return on Assets ranged from a high of 1.40% in Q2 2025 and a low of -0.61% during Q1 2023.
  • Moreover, its 3-year median value for Return on Assets was 0.13% (2024), whereas its average is 0.23%.
  • Per our database at Business Quant, Coherus Oncology's Return on Assets crashed by 56bps in 2021 and then skyrocketed by 133bps in 2024.
  • Quarterly analysis of 5 years shows Coherus Oncology's Return on Assets stood at -0.40% in 2021, then declined by 16bps to -0.57% in 2022, then rose by 17bps to -0.39% in 2023, then surged by 133bps to 0.94% in 2024, then spiked by 84bps to 1.13% in 2025.
  • Its Return on Assets stands at 1.13% for Q3 2025, versus 1.40% for Q2 2025 and 0.65% for Q1 2025.